Pages that link to "Q40569480"
Jump to navigation
Jump to search
The following pages link to The long-lasting antidepressant effects of rapastinel (GLYX-13) are associated with a metaplasticity process in the medial prefrontal cortex and hippocampus (Q40569480):
Displaying 26 items.
- IGFBP2 Produces Rapid-Acting and Long-Lasting Effects in Rat Models of Posttraumatic Stress Disorder via a Novel Mechanism Associated with Structural Plasticity (Q33762274) (← links)
- GLYX-13, a NMDA Receptor Glycine-Site Functional Partial Agonist, Attenuates Cerebral Ischemia Injury In Vivo and Vitro by Differential Modulations of NMDA Receptors Subunit Components at Different Post-Ischemia Stage in Mice (Q33780749) (← links)
- The Development of Rapastinel (Formerly GLYX-13); A Rapid Acting and Long Lasting Antidepressant (Q34519141) (← links)
- Synaptic Plasticity, Metaplasticity and Depression (Q37668039) (← links)
- Modulation of the activity of N-methyl-d-aspartate receptors as a novel treatment option for depression: current clinical evidence and therapeutic potential of rapastinel (GLYX-13). (Q37741989) (← links)
- New Treatment Strategies of Depression: Based on Mechanisms Related to Neuroplasticity. (Q38685420) (← links)
- What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities. (Q39006234) (← links)
- Enhancing NMDA Receptor Function: Recent Progress on Allosteric Modulators (Q39121207) (← links)
- BDNF release and signaling are required for the antidepressant actions of GLYX-13. (Q47331962) (← links)
- NYX-2925 is a novel NMDA receptor-specific spirocyclic-β-lactam that modulates synaptic plasticity processes associated with learning and memory (Q47383734) (← links)
- Fast-acting antidepressants rapidly stimulate ERK signaling and BDNF release in primary neuronal cultures (Q47388230) (← links)
- A brief history of antidepressant drug development: from tricyclics to beyond ketamine (Q47640228) (← links)
- Beyond Ketamine: New Approaches to the Development of Safer Antidepressants (Q47963007) (← links)
- GLYX-13 Produces Rapid Antidepressant Responses with Key Synaptic and Behavioral Effects Distinct from Ketamine. (Q48472517) (← links)
- Alcohol-Induced Increases in Inflammatory Cytokines Are Attenuated by Nicotine in Region-Selective Manner in Male Rats (Q49236388) (← links)
- Dendritic structural plasticity and neuropsychiatric disease. (Q52653221) (← links)
- Mechanisms of ketamine action as an antidepressant. (Q52658612) (← links)
- Convergent Mechanisms Underlying Rapid Antidepressant Action. (Q52667723) (← links)
- Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants (Q57293270) (← links)
- Scale-Up Synthesis and Identification of GLYX-13, a NMDAR Glycine-Site Partial Agonist for the Treatment of Major Depressive Disorder (Q88473811) (← links)
- Glycinergic signaling in the human nervous system: An overview of therapeutic drug targets and clinical effects (Q89329522) (← links)
- GLYX-13 pretreatment ameliorates long-term isoflurane exposure-induced cognitive impairment in mice (Q90175454) (← links)
- Positive N-Methyl-D-Aspartate Receptor Modulation by Rapastinel Promotes Rapid and Sustained Antidepressant-Like Effects (Q90452439) (← links)
- Neurobiology of rapid-acting antidepressants: convergent effects on GluA1-synaptic function (Q92512363) (← links)
- Esketamine and rapastinel, but not imipramine, have antidepressant-like effect in a treatment-resistant animal model of depression (Q92966514) (← links)
- Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments (Q93177074) (← links)